Welcome to our dedicated page for ReShape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on ReShape Lifesciences stock.
RSLS was the Nasdaq ticker symbol for ReShape Lifesciences Inc., a physician-led weight loss and metabolic health-solutions company focused on device-based treatments for obesity and metabolic disease. News flow around RSLS has covered both the company e2 80 99s product developments in surgical and medical instruments and its major corporate transactions, including a reverse merger and asset sale.
ReShape Lifesciences frequently announced updates related to its obesity treatment technologies. These included communications about the FDA-approved Lap-Band ae System and Lap-Band ae 2.0 FLEX, the Obalon ae swallowable intragastric balloon technology, and the investigational Diabetes Bloc-Stim Neuromodulation ae (DBSN ae) system for type 2 diabetes and metabolic disorders. The company also issued news about its intellectual property, such as the issuance of a U.S. patent titled e2 80 9cIntragastric Device e2 80 9d covering a swallowable, degradable intragastric balloon system.
In addition to product and IP announcements, RSLS-related news has focused heavily on strategic and financial events. ReShape Lifesciences disclosed a merger agreement with Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases, and later reported shareholder approvals, Nasdaq listing approvals, and completion of the merger. Following the closing on August 15, 2025, the public company was renamed Vyome Holdings, Inc. and began trading under the symbol HIND. News items also addressed the sale of substantially all of ReShape e2 80 99s assets to an affiliate of Biorad Medisys, reverse stock split approvals and implementation, cost reduction measures, and Nasdaq compliance updates.
Investors and observers using this RSLS news page can review historical coverage of ReShape Lifesciences e2 80 99 product announcements, patent milestones, corporate governance changes, shareholder meetings, merger progress with Vyome Therapeutics, and the asset sale to Biorad Medisys. This context helps explain how the former RSLS-listed company transitioned into Vyome Holdings, Inc. and why the stock now trades under the HIND symbol on The Nasdaq Capital Market.
ReShape Lifesciences (Nasdaq: RSLS) reported Q3 2022 results with revenues of $2.8 million, down 24.5% year-over-year, primarily due to a focus shift towards U.S. sales. Gross profit margin increased to 75.1% as domestic sales rose. The company appointed Paul F. Hickey as CEO and launched a targeted digital marketing strategy, reducing patient lead costs by over 50%. Despite the revenue decline, the firm anticipates revenue growth due to recent FDA product clearances and updates from ASMBS supporting bariatric surgery, aiming for profitability through strategic adjustments.
ReShape Lifesciences (RSLS) has announced a securities purchase agreement with an institutional investor for a registered direct offering of 2,884,615 shares of common stock at $0.26 per share and 2,500 shares of Series D Preferred Stock. The offering is expected to close by November 9, 2022, with total gross proceeds expected to be approximately $750,000. The proceeds will be used for commercialization, clinical development, and working capital. Additionally, existing warrants will be amended to reduce the exercise price to $0.30 per share.
ReShape Lifesciences (Nasdaq: RSLS) will release its third quarter financial results on November 14, 2022, before market opening. A corporate update will accompany these results. Following the announcement, management will host a conference call at 8:00 am ET, available via their website. ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System, aimed at treating obesity and metabolic diseases.
ReShape Lifesciences (Nasdaq: RSLS) presented data on its Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device at the Obesity Society Annual Meeting in San Diego. The device demonstrated safety and efficacy in a swine model of type 2 diabetes, reducing glucose variability during tests. The DBSN™ device employs bioelectronic modulation to enhance insulin production while blocking glucose release from the liver. The CEO highlighted the technology's potential in treating diabetes and reducing medication dependence. The company continues development with a focus on metabolic disorders.
SAN CLEMENTE, Calif., Nov. 02, 2022 – ReShape Lifesciences (Nasdaq: RSLS) announces that CEO Paul F. Hickey and CFO Tom Stankovich will present at the Q4 Investor Summit on November 14 at 1:30 p.m. ET. They will highlight the next-generation Lap-Band® program and the reshape
ReShape Lifesciences (Nasdaq: RSLS) announced updated guidelines from the ASMBS and IFSO for metabolic and bariatric surgery, which now recommend surgery for individuals with a BMI of 35 or more, regardless of comorbidities. The Lap-Band® is highlighted as the only FDA-approved device for weight reduction in this category. The new guidelines may significantly increase the number of eligible patients, enhancing access to weight loss procedures, particularly for those with a BMI over 30 and related health issues. These changes are expected to positively impact demand for Lap-Band® procedures and potentially boost revenues.
ReShape Lifesciences (Nasdaq: RSLS) announced promising results for its Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system, detailed in the journal Frontiers in NeuroScience. The study showed that DBSN™ effectively improved glycemic control in type 2 diabetic rat and swine models by blocking and stimulating vagus nerve signals. The therapy may reduce insulin resistance while increasing insulin release, positioning it as a novel, adjustable treatment for type 2 diabetes. This research was supported by NIH Small Business Innovation Research grants, confirming its potential impact on diabetes management.
ReShape Lifesciences (Nasdaq: RSLS) announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) has issued a new Consensus Statement on the management of Lap-Band® patients. This consensus, developed by 39 expert surgeons, includes 34 statements focused on aftercare practices and the efficacy of Lap-Band® as a weight loss solution. The report emphasizes the importance of behavioral health and nutrition in post-surgery care, aligning with ReShape's reshapecare™ program designed to support patients through virtual health coaching.
ReShape Lifesciences (Nasdaq: RSLS) has received a $300,000 Small Business Innovation Research (SBIR) grant to develop the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device for treating hypoglycemia. This device uses proprietary vagus nerve block technology in conjunction with a continuous glucose monitor. The funding will enable further development of the device, which aims to enhance glucose management and reduce hypoglycemia risks in diabetes patients. The technology is backed by 48 patents and has shown safety and efficacy in previous studies.
ReShape Lifesciences (Nasdaq: RSLS) announced participation in one-on-one meetings with institutional investors at the A.G.P. Virtual MedTech Conference on September 21, 2022. The company, focused on weight loss and metabolic health, offers various solutions, including the FDA-approved Lap-Band® Program and the ReShape Vest™ System. For more information, interested investors can contact their A.G.P. representative.
FAQ
What is the current stock price of ReShape Lifesciences (RSLS)?
What is the market cap of ReShape Lifesciences (RSLS)?
